\
&
Contact us
\
&
Contact us
Published on | 1 hour ago
ProgrammesThe ERC plans to launch the grant competitions under its 2027 Work Programme between July 2026 and June 2027. The ERC Scientific Council has made decisions on new changes in response to the evolving career patterns among researchers and the sharp increase in applications, which is placing growing pressure on peer reviewers and the ERC executive agency.
The changes relate to:
The changes are available in more detail in an ERC news article accompanied by an open letter from the ERC President Maria Leptin. The new eligibility windows for ERC Starting and Consolidator Grants and the new application and resubmission restrictions are announced ahead of the publication of the 2027 ERC Work Programme, which is foreseen in summer 2026. This is done to allow the scientific community, including prospective applicants, to be prepared for the changes ahead of the publication of the individual calls.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital Europe AI Continent Advanced Digital Skills Deployment: Best use of technologies
The following call topics under the Digital Europe programme are now open for submission: Apply AI: Piloting AI-based image screening in medical centres Digital solutions for regulatory compliance through data Advanced Digital Skills for AI Uptake in Health EdTech Accelerator Digital Skills and Jobs Platform: The National Coalitions for Digi... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
